Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine

Age and Ageing

Volumn 35, Issue 4, 2006, Pages 365-371

  López Pousa, Secundino ^a   Olmo, Joseph Garre ^a   Franch, Joan Vilalta ^b   Estrada, Antoni Turon ^b   Cors, Olga Soler ^b   Nierga, Imma Pericot ^b   Gelada Batlle, Esther ^b  

^a Hospital de Santa Caterina   (Spain)

^b Dementia Unit   (Spain)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Co morbidity; Elderly; Mortality

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARDIOVASCULAR AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HYPNOTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG FATALITY; DRUG TOLERABILITY; DRUG USE; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RATING SCALE; RETROSPECTIVE STUDY; REVIEW; SCORING SYSTEM; SEX DIFFERENCE; STANDARDIZATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHI-SQUARE DISTRIBUTION; CHOLINESTERASE INHIBITORS; COHORT STUDIES; COMORBIDITY; FEMALE; GALANTAMINE; HUMANS; INDANS; MALE; MIDDLE AGED; PIPERIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33745365624     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afj083     Document Type: Review

References (43)

1. Doody RS. Current Treatments for Alzheimer's disease: Cholinesterase inhibitors. J Clin Psychiatry 2003; 64 (Suppl 9): 11-7.
2. Ritchie CW, Ames D, Clayton T, Lai R. Metaanalysis of randomized trials of the effectiveness and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry 2004; 12: 358-69.
3. Blass JP, Cyrus PA, Bieber F, Gulanski B. Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and tolerability of metrifonate in patients with probable Alzheimer disease. The Metrifonate Study Group. Alzheimer Dis Assoc Disord 2000; 14: 39-45.
4. Qizilbash N, Birks J, Lopez-Arrieta J, Lewington S, Szeto S. Tacrine for Alzheimer's disease. Cochrane Database Syst Rev 2000; issue 2: CD000202.
5. Turon-Estrada A, Lopez-Pousa S, Gelada-Batlle E et al. Tolerancia y acontecimientos adversos del tratamiento con inhibidores de la acetilcolinesterasa en una muestra clínica de pacientes con enfermedad de Alzheimer de gravedad ligera y moderada durante un periodo de 6 meses. Rev Neurol 2003; 36: 421-4.
6. Knopman D, Schneider L, Davis K et al. Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality, Tacrine Study Group. Neurology 1996; 47: 166-77.
7. Smith F, Talwalker S, Gracon S, Srirama M. The use of survival analysis techniques in evaluating the effect of long-term tacrine (Cognex) treatment on nursing home placement and mortality in patients with Alzheimer's disease. J Biopharm Stat 1996; 6: 395-409.
8. Ott BR, Lapane KL. Tacrine therapy is associated with reduced mortality in nursing home residents with dementia. J Am Geriatr Soc 2002; 50: 35-40.
9. Food and Drug Administration. Alert for Healthcare Professionals on Galantamine hydrochloride [FDA ALERT 02/23/ 2005]. Available at: http//www.fda.gov/cder/infosheets/professionals/galantaminePIS.pdf
10. Folstein MF, Folstein SE, McHugh PR. Mini Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
11. Blessed G, Tomilson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114: 797-811.
12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44.
13. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136-9.
14. Aguero-Torres H, Fratiglioni L, Guo Z, Viitanen M, Winblad B. Mortality from dementia in advanced age: A 5-year followup study of incident dementia cases. J Clin Epidemiol 1999; 52: 737-43.
15. Gambassi G, Lapane KL, Landi F, Sgadari A, Mor V, Bernabie R. Gender differences in the relation between comorbidity and mortality of patients with Alzheimer's disease. Systematic Assessment of Geriatric drug use via Epidemiology (SAGE) Study Group. Neurology 1999; 53: 508-16.
16. Lapane KL, Gambassi G, Landi F, Sgadari A, Mor V, Bernabei R. Gender differences in predictors of mortality in nursing home residents with AD. Neurology 2001; 56: 650-4.
17. Lopez OL, Wisniewski SR, Becker JT, Boller F, DeKosky ST. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol 1999; 56: 1266-72.
18. Moritz DJ, Fox PJ, Luscombe FA, Kraemer HC. Neurological and psychiatric predictors of mortality in patients with Alzheimer disease in California. Arch Neurol. 1997; 54: 878-85.
19. Stump TE, Callahan CM, Hendrie HC. Cognitive impairment and mortality in older primary care patients. J Am Geriatr Soc 2001; 49: 934-40.
20. Ueki A, Shinjo H, Shimode H, Nakajima T, Morita Y. Factors associated with mortality in patients with early-onset Alzheimer's disease: A five-year longitudinal study. Int J Geriatr Psychiatry. 2001; 16: 810-5.
21. Perras C, Shukla VK, Lessard C, Skidmore B, Bergman H, Gauthier S. Cholinesterase inhibitors for Alzheimer's disease: A systematic review of randomized controlled trials. Health Technol Assess 2005; 58: 1-117.
22. Salloway S, Ferris S, Kluger A et al. Efficacy of donepezil in mild cognitive impairment: A randomized placebo-controlled trial. Neurology 2004; 63: 651-7.
23. Petersen RC, Thomas RG, Grundman M et al. Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352: 2379-88.
24. Wilcock G, Howe I, Coles H et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 2003; 20: 777-89.
25. Aguglia E, Onor ML, Saina M, Maso E. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Curr Med Res Opin 2004; 20: 1747-52.
26. Courtney C, Farrell D, Gray R et al. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial. Lancet 2004; 363: 2105-15.
27. Wallin AK, Gustafson L, Sjogren M, Wattmo C, Minthon L. Five-year outcome of cholinergic treatment of Alzheimer's disease: Early response predicts prolonged time until nursing home placement, but does not alter life expectancy. Dement Geriatr Cogn Disord 2004; 18: 197-206.
28. Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002; 72: 310-14.
29. Buccofusco JJ. The role of central cholinergic neurons in the regulation of blood pressure and in experimental hypertension. Pharmacol Rev 1996; 48: 179-211.
30. McLaren AT, Allen J, Murray A, Ballard CG, Kenny RA. Cardiovascular effects of donepezil in patients with dementia. Dement Geriatr Cogn Disord 2003; 15: 183-8.
31. Herrmann N, Lanctot KL. Do atypical antipsychotics cause stroke? CNS Drugs 2005; 19: 105-23.
32. Gill SS, Rochon PA, Herrmann N et al. Atypical antipsychotic drugs and risk of ischaemic stroke: Population based retrospective cohort study. Br Med J 2005; 330: 445-8.
33. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 1996; 7: 293-303.
34. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998; 158: 1021-31.
35. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50: 136-45.
36. Homma A, Imai Y, Hariguchi S, Hasegawa K, Kameyama M, Nishimura T. Late phase II clinical study of acetylcholinesterase inhibitor E2020 in patients with Alzheimer-type dementia: 24-48-weeks double-blind, placebocontrolled study. Rinsho Hyoka [Clin Eval] 1998; 26: 209-231.
37. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, Rogers SL, Friedhoff LT. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237-244.
38. Mohs RC, Doody RS, Morris JC et al.; '312' Study Group. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481-8.
39. Tariot PN, Cummings JL, Katz IR et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001; 49: 1590-9.
40. Winblad B, Engedal K, Soininen H et al.; Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001; 57: 489-95.
41. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with 6-month extension. The Galantamine USA-10 Study Group. Neurology 2000; 54: 2261-8.
42. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S. Ding C. A 5-month, randomized, placebo-controlled trial galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269-2276.
43. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson Effects of a flexible galantamine dose in Alzheimer's disease: Randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001; 71: 589-95.